

## Bayesian Dosing Do's & Don'ts



Dr. Shivani Patel, PharmD, BCPS Clinical Pharmacy Specialist, Infectious Diseases Memorial Hermann Health System



Dr. Dustin Orvin, PharmD, BCPS Clinical Pharmacy Specialist St. Joseph's/Candler Health System



## Do's

- · Do keep in constant contact with your IT team
- Do be available and ready to answer questions for your staff
- Do have staff shadow other pharmacists to confirm dose selections and protocol adherence
- Do keep a living Frequently Asked Questions document for staff to reference
- Do follow discontinued vancomycin orders
- Do help staff manage cases of therapy not warranted or concern over random morning levels and toxicity
- Do provide open lines of communication for stakeholder feedback
- Do continuously utilize data to refine your process
- Do communicate your success stories early and often as this improves staff confidence and increases buy-in



- Don't take monitoring for granted when evaluating Bayesian dosing; consider your goals and how to practically capture data
- Don't assume AUC or Bayesian dosing is too expensive without evaluating the benefits
- Don't underestimate the financial impact of AKI reduction
- Don't assume that all staff will do everything exactly as you intended; address variations with education and retraining
- Don't assume that the written protocol will not need to be refined post launch; the protocol should be a considered a "living document"
- Don't forget to prepare for Electronic Health Record (EHR) downtime if you are a fully integrated site, by training staff to handle these situations

Ready to see how seamlessly DoseMeRx integrates into your workday? Get in touch to start your <u>free trial</u>.

For more tips and strategies, watch our webinar.